Vasomotor symptoms (VMS) affect 2 out of 3 women during menopause and are highly
disruptive and intolerable. They exert a negative impact on a woman's physical and mental …

The short answer to this question could be that they do not work, but that is not true. It is
much more likely that a turf war is developing between psychiatrists and gynaecologists …

OBJECTIVE: The objective of the study was to assess the efficacy and safety of
desvenlafaxine (administered as desvenlafaxine succinate) for menopausal vasomotor …

Menopause and the preceding climacteric years are normal aspects of the reproductive life
cycle in women. However, the fluctuations and declines in hormone levels are physiologic …

Objective Non-hormonal treatment for menopausal vasomotor symptoms (VMS) is needed in
women in whom there are medical or personal concerns on the use of hormone therapy …

Aim To review non-hormonal therapy options for menopausal vasomotor symptoms. The
current EMAS position paper aims to provide to provide guidance for managing peri-and …

Objective: To examine the effectiveness of oral hormone replacement therapy (HRT) with
regard to hot flushes and night sweats, which are vasomotor symptoms commonly …

Objective This trial examined diaries of hot flash events reported upon occurrence to assess
the test/retest reliability of the diaries and their ability to measure treatment effects on hot …

Publisher Summary Hot flashes are the most common symptom associated with
menopause, although prevalence estimates are lower in some rural and non-Western areas …

Perimenopause is often marked by vasomotor symptoms and dysphoria. Antidepressant
studies have demonstrated decreased frequency and severity of hot flashes in breast cancer …